在CYP2C9基因多态性和亚齐尔沙坦在体外代谢之间的关系
Su-Su Bao1, Peng-Fei Tang1, Quan Zhou2
1Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, China.
Expert opinion on drug metabolism & toxicology
|September 24, 2024
概括
CYP2C9基因变异显著改变阿齐尔萨坦代谢,其中一些变异增加了清除,而另一些变异降低了清除. 分子对接揭示了改变的结合能,影响了药物的疗效,并为精准医学策略提供了信息.
科学领域:
- 药物基因组学 药物基因组学
- 药物新陈代谢 药物新陈代谢
- 酶动力学 酶动力学
背景情况:
- 细胞染色体P450 2C9 (CYP2C9) 基因多态性影响药物代谢.
- 在不同的CYP2C9变体中,酶活性显著变化.
研究的目的:
- 为了研究CYP2C9基因多态化对阿齐尔沙坦代谢的影响.
- 通过分子对接来阐明改变酶功能的机制.
主要方法:
- 用表达野生类型和38种CYP2C9变异的昆虫显微体化阿齐尔沙坦.
- 使用HPLC-MS/MS. 量化O-desethyl阿齐尔沙坦代谢物.
- 计算酶动力学参数和分子对接模拟.
主要成果:
- 三种CYP2C9变体显示,阿齐尔沙坦的内在清除 (CLint) 显著增加 (170%-275%).
- 二十八种变种显示显著降低了CLint (3%-63%).
- 与野生型相比,分子对接表明CYP2C9*2和*3变体的结合能量较低.
结论:
- CYP2C9的多态性对阿齐尔沙坦的代谢有很大影响.
- 这些发现为体内研究和临床应用在精密医学领域提供了基础.
- 这项研究扩展了CYP2C9基因与药物相互作用数据库,用于阿齐尔沙坦治疗策略.
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
103
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
103
Factors Affecting Drug Biotransformation: Biological
125
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
125
Drug Metabolism: Phase II Reactions
3.7K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.7K
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
199
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
The drug's acidity or basicity is essential in...
199
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
191
Renal clearance of a drug is influenced by various factors, including its physicochemical properties and plasma levels. These factors play a significant role in determining how efficiently the kidneys eliminate a drug.
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
191
Phase II Reactions: Glucuronidation
314
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
314


